How to use the speech recognition tool?
This trial does use Clemastine fumarat as a remyelinating agent targeting the
muscarinic receptor on oligodendrocytes around the optic nerve.
Status of the trial: Active, Recruiting
Orphan Drug Recognition: NA
- Opening Date: 0000-00-00
- Closing Date: 2022-08-31
Inclusion: Patients with acute optic neuritis including the rare forms, inclusion within 2 weeks after onset of ION, RION, CRION, etc
Exclusion: Major ophthalmological disease, myopia >7dpt, simultaneous bilateral ON, pregnancy, other study involvement, (please see protocol for full list)
Funder Type: other
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
- Neuro-Ophthalmology Rare Diseases (WG2)
- Retinal Rare Eye Diseases (WG1)
This ERN is supported by: